title: The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells.
abstract: We have demonstrated that the peptide L-2 designed from an alanine scanning of the Limulus-derived LALF32-51 region is a potential candidate for the anticancer therapy and its cell-penetrating capacity is an associated useful property. By the modification in the primary structure of L-2, a second-generation peptide (CIGB-552) was developed. However, the molecular mechanism underlying its cytotoxic activity remains partially unknown. In this study, it was shown that CIGB-552 increases the levels of COMMD1, a protein involved in copper homeostasis, sodium transport, and the NF-κB signaling pathway. We found that CIGB-552 induces ubiquitination of RelA and inhibits the antiapoptotic activity regulated by NF-κB, whereas the knockdown of COMMD1 blocks this effect. We also found that CIGB-552 decreases the antioxidant capacity and induces the peroxidation of proteins and lipids in the tumor cells. Altogether, this study provides new insights into the mechanism of action of the peptide CIGB-552, which could be relevant in the design of future anticancer therapies.
authors: Department of Genomic, Center for Genetic Engineering and Biotechnology, Cubanacan, P.O. Box 6162, 10600 Havana, Cuba.
authors: Julio R
authors: JR
authors: Fernández Massó
authors: Brizaida
authors: B
authors: Oliva Argüelles
authors: Yelaine
authors: Y
authors: Tejeda
authors: Soledad
authors: S
authors: Astrada
authors: Hilda
authors: H
authors: Garay
authors: Osvaldo
authors: O
authors: Reyes
authors: Livan
authors: L
authors: Delgado-Roche
authors: Mariela
authors: M
authors: Bollati-Fogolín
authors: Maribel G
authors: MG
authors: Vallespí
references: Anal Biochem. 1996 Jul 15;239(1):70-6
references: 8660627
references: J Immunol. 1998 Sep 1;161(5):2524-32
references: 9725252
references: Am J Cancer Res. 2011;1(2):192-221
references: 21969033
references: Mol Cell Biol. 2007 Jun;27(11):4142-56
references: 17371845
references: J Biol Chem. 2012 Jan 20;287(4):2485-99
references: 22130675
references: J Biol Chem. 2001 Jun 8;276(23):19746-52
references: 11274209
references: Biochem J. 2007 Jan 1;401(1):1-11
references: 17150040
references: Nat Methods. 2012 Jul;9(7):671-5
references: 22930834
references: BMC Bioinformatics. 2009 Dec 15;10:421
references: 20003500
references: BMC Mol Biol. 2010 Sep 21;11:74
references: 20858237
references: Nucleic Acids Res. 2002 May 1;30(9):e36
references: 11972351
references: Biochem J. 2006 Aug 15;398(1):63-71
references: 16573520
references: Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
references: 12184808
references: Anal Biochem. 1997 Sep 5;251(2):206-9
references: 9299017
references: Drug Discov Today. 2010 Jan;15(1-2):40-56
references: 19879957
references: Cancer Res. 2010 Jan 1;70(1):139-49
references: 20048074
references: Anal Biochem. 1976 May 7;72:248-54
references: 942051
references: Nucleic Acids Res. 2007 Jan;35(Database issue):D805-9
references: 17068075
references: Drug Resist Updat. 2004 Apr;7(2):97-110
references: 15158766
references: J Biol Chem. 2010 Sep 10;285(37):28991-9000
references: 20595380
references: J Pept Sci. 2010 Jan;16(1):40-7
references: 19908203
references: J Immunol Methods. 1984 Sep 4;72(2):313-40
references: 6206159
references: EMBO J. 2007 Jan 24;26(2):436-47
references: 17183367
references: Nat Immunol. 2011 Jul 19;12(8):715-23
references: 21772280
references: Cancers (Basel). 2010 May 17;2(2):859-84
references: 24281098
references: EMBO Rep. 2009 Apr;10(4):381-6
references: 19270718
references: Mol Cancer Res. 2010 Jan;8(1):119-30
references: 20068069
references: Cell Cycle. 2007 Mar 15;6(6):672-6
references: 17361106
references: J Hered. 2005;96(7):803-11
references: 16267171
references: Chem Res Toxicol. 1998 Oct;11(10):1184-94
references: 9778315
references: Traffic. 2009 May;10(5):514-27
references: 19220812
references: Biochem Biophys Res Commun. 2011 Aug 5;411(3):506-11
references: 21741370
references: Biochem J. 2009 Jan 15;417(2):601-9
references: 18795889
references: Expert Rev Mol Med. 2009 Aug 27;11:e26
references: 19709449
references: PLoS One. 2009 Oct 05;4(10):e7332
references: 19802386
references: J Clin Invest. 2010 Jun;120(6):2119-30
references: 20458141